| Product Code: ETC7548798 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Dhaval Chaurasia | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 India Neurodegenerative Drugs Market Overview |
3.1 India Country Macro Economic Indicators |
3.2 India Neurodegenerative Drugs Market Revenues & Volume, 2021 & 2031F |
3.3 India Neurodegenerative Drugs Market - Industry Life Cycle |
3.4 India Neurodegenerative Drugs Market - Porter's Five Forces |
3.5 India Neurodegenerative Drugs Market Revenues & Volume Share, By Drug Class, 2021 & 2031F |
3.6 India Neurodegenerative Drugs Market Revenues & Volume Share, By Indication, 2021 & 2031F |
3.7 India Neurodegenerative Drugs Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
4 India Neurodegenerative Drugs Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of neurodegenerative disorders in India |
4.2.2 Growing awareness about the availability of neurodegenerative drugs |
4.2.3 Advancements in healthcare infrastructure and technology in India |
4.3 Market Restraints |
4.3.1 High cost of neurodegenerative drugs limiting access to treatment |
4.3.2 Stringent regulatory requirements for drug approval in India |
5 India Neurodegenerative Drugs Market Trends |
6 India Neurodegenerative Drugs Market, By Types |
6.1 India Neurodegenerative Drugs Market, By Drug Class |
6.1.1 Overview and Analysis |
6.1.2 India Neurodegenerative Drugs Market Revenues & Volume, By Drug Class, 2021- 2031F |
6.1.3 India Neurodegenerative Drugs Market Revenues & Volume, By Dopamine agonist, 2021- 2031F |
6.1.4 India Neurodegenerative Drugs Market Revenues & Volume, By Decarboxylase inhibitors, 2021- 2031F |
6.1.5 India Neurodegenerative Drugs Market Revenues & Volume, By Cholinesterase Inhibitors, 2021- 2031F |
6.1.6 India Neurodegenerative Drugs Market Revenues & Volume, By Immunomodulators, 2021- 2031F |
6.1.7 India Neurodegenerative Drugs Market Revenues & Volume, By Others, 2021- 2031F |
6.2 India Neurodegenerative Drugs Market, By Indication |
6.2.1 Overview and Analysis |
6.2.2 India Neurodegenerative Drugs Market Revenues & Volume, By Parkinsons Disease, 2021- 2031F |
6.2.3 India Neurodegenerative Drugs Market Revenues & Volume, By Alzheimers Disease, 2021- 2031F |
6.2.4 India Neurodegenerative Drugs Market Revenues & Volume, By Multiple Sclerosis, 2021- 2031F |
6.2.5 India Neurodegenerative Drugs Market Revenues & Volume, By Others, 2021- 2031F |
6.3 India Neurodegenerative Drugs Market, By Distribution Channel |
6.3.1 Overview and Analysis |
6.3.2 India Neurodegenerative Drugs Market Revenues & Volume, By Hospital Pharmacies, 2021- 2031F |
6.3.3 India Neurodegenerative Drugs Market Revenues & Volume, By Online Providers, 2021- 2031F |
6.3.4 India Neurodegenerative Drugs Market Revenues & Volume, By Drug Stores and Retail Pharmacies, 2021- 2031F |
7 India Neurodegenerative Drugs Market Import-Export Trade Statistics |
7.1 India Neurodegenerative Drugs Market Export to Major Countries |
7.2 India Neurodegenerative Drugs Market Imports from Major Countries |
8 India Neurodegenerative Drugs Market Key Performance Indicators |
8.1 Number of patients diagnosed with neurodegenerative disorders annually |
8.2 Adoption rate of new neurodegenerative drugs in the Indian market |
8.3 Research and development investments in neurodegenerative drug development |
9 India Neurodegenerative Drugs Market - Opportunity Assessment |
9.1 India Neurodegenerative Drugs Market Opportunity Assessment, By Drug Class, 2021 & 2031F |
9.2 India Neurodegenerative Drugs Market Opportunity Assessment, By Indication, 2021 & 2031F |
9.3 India Neurodegenerative Drugs Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
10 India Neurodegenerative Drugs Market - Competitive Landscape |
10.1 India Neurodegenerative Drugs Market Revenue Share, By Companies, 2024 |
10.2 India Neurodegenerative Drugs Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here